Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren + amlodipine versus amlodipine dose escalation in patients with hypertension not adequately controlled on amlodipine 5 mg
2004-002410-11Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aliskiren and amlodipine in essential hypertension (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in mean sitting diastolic blood pressure. Started Dec 2004; status: completed.
02
Drugs
aliskirenamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2004-002410-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002410-11.